Esperion Therapeutics (NASDAQ:ESPR) Given "Buy" Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR - Free Report) in a research report released on Tuesday morning,Benzinga reports. They currently have a $16.00 target price on the biopharmaceutical company's stock.

Several other brokerages have also recently weighed in on ESPR. JMP Securities reissued a "market outperform" rating and set a $7.00 price objective on shares of Esperion Therapeutics in a report on Thursday, January 23rd. The Goldman Sachs Group began coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 target price for the company. StockNews.com lowered Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Needham & Company LLC restated a "buy" rating and set a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, Cantor Fitzgerald began coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They set an "overweight" rating and a $8.00 target price for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $6.75.

Esperion Therapeutics Stock Performance

NASDAQ:ESPR traded down $0.01 on Tuesday, hitting $1.87. 1,708,732 shares of the stock were exchanged, compared to its average volume of 4,447,893. The stock has a market capitalization of $367.47 million, a price-to-earnings ratio of -2.91 and a beta of 1.01. Esperion Therapeutics has a 52 week low of $1.58 and a 52 week high of $3.94. The company's 50-day moving average price is $2.24 and its 200 day moving average price is $2.12.

Hedge Funds Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Traphagen Investment Advisors LLC acquired a new position in shares of Esperion Therapeutics in the 3rd quarter valued at approximately $27,000. Cibc World Markets Corp acquired a new position in Esperion Therapeutics during the 4th quarter worth approximately $39,000. SJS Investment Consulting Inc. acquired a new position in Esperion Therapeutics during the 4th quarter worth approximately $55,000. Versor Investments LP acquired a new position in Esperion Therapeutics during the 3rd quarter worth approximately $44,000. Finally, SLT Holdings LLC acquired a new position in Esperion Therapeutics during the 4th quarter worth approximately $66,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.